These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 17640949)

  • 1. Ex vivo occupancy of gamma-secretase inhibitors correlates with brain beta-amyloid peptide reduction in Tg2576 mice.
    Goldstein ME; Cao Y; Fiedler T; Toyn J; Iben L; Barten DM; Pierdomenico M; Corsa J; Prasad CV; Olson RE; Li YW; Zaczek R; Albright CF
    J Pharmacol Exp Ther; 2007 Oct; 323(1):102-8. PubMed ID: 17640949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of (S)-2-((S)-2-(3,5-difluorophenyl)-2-hydroxyacetamido)-N-((S,Z)-3-methyl-4-oxo-4,5-dihydro-3H-benzo[d][1,2]diazepin-5-yl)propanamide (BMS-433796): a gamma-secretase inhibitor with Abeta lowering activity in a transgenic mouse model of Alzheimer's disease.
    Prasad CV; Zheng M; Vig S; Bergstrom C; Smith DW; Gao Q; Yeola S; Polson CT; Corsa JA; Guss VL; Loo A; Wang J; Sleczka BG; Dangler C; Robertson BJ; Hendrick JP; Roberts SB; Barten DM
    Bioorg Med Chem Lett; 2007 Jul; 17(14):4006-11. PubMed ID: 17502137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.
    Barten DM; Guss VL; Corsa JA; Loo A; Hansel SB; Zheng M; Munoz B; Srinivasan K; Wang B; Robertson BJ; Polson CT; Wang J; Roberts SB; Hendrick JP; Anderson JJ; Loy JK; Denton R; Verdoorn TA; Smith DW; Felsenstein KM
    J Pharmacol Exp Ther; 2005 Feb; 312(2):635-43. PubMed ID: 15452193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide].
    Best JD; Jay MT; Otu F; Ma J; Nadin A; Ellis S; Lewis HD; Pattison C; Reilly M; Harrison T; Shearman MS; Williamson TL; Atack JR
    J Pharmacol Exp Ther; 2005 May; 313(2):902-8. PubMed ID: 15743924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
    Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
    J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse.
    Hyde LA; McHugh NA; Chen J; Zhang Q; Manfra D; Nomeir AA; Josien H; Bara T; Clader JW; Zhang L; Parker EM; Higgins GA
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1133-43. PubMed ID: 16946102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575).
    Lanz TA; Hosley JD; Adams WJ; Merchant KM
    J Pharmacol Exp Ther; 2004 Apr; 309(1):49-55. PubMed ID: 14718585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    Imbimbo BP; Del Giudice E; Colavito D; D'Arrigo A; Dalle Carbonare M; Villetti G; Facchinetti F; Volta R; Pietrini V; Baroc MF; Serneels L; De Strooper B; Leon A
    J Pharmacol Exp Ther; 2007 Dec; 323(3):822-30. PubMed ID: 17895400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Anderson JJ; Holtz G; Baskin PP; Turner M; Rowe B; Wang B; Kounnas MZ; Lamb BT; Barten D; Felsenstein K; McDonald I; Srinivasan K; Munoz B; Wagner SL
    Biochem Pharmacol; 2005 Feb; 69(4):689-98. PubMed ID: 15670587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of gamma-secretase and BACE1 inhibition on brain Abeta levels in vitro and in vivo.
    Elvang AB; Volbracht C; Pedersen LØ; Jensen KG; Karlsson JJ; Larsen SA; Mørk A; Stensbøl TB; Bastlund JF
    J Neurochem; 2009 Sep; 110(5):1377-87. PubMed ID: 19519664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo beta-secretase 1 inhibition leads to brain Abeta lowering and increased alpha-secretase processing of amyloid precursor protein without effect on neuregulin-1.
    Sankaranarayanan S; Price EA; Wu G; Crouthamel MC; Shi XP; Tugusheva K; Tyler KX; Kahana J; Ellis J; Jin L; Steele T; Stachel S; Coburn C; Simon AJ
    J Pharmacol Exp Ther; 2008 Mar; 324(3):957-69. PubMed ID: 18156464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor.
    Grimwood S; Hogg J; Jay MT; Lad AM; Lee V; Murray F; Peachey J; Townend T; Vithlani M; Beher D; Shearman MS; Hutson PH
    Neuropharmacology; 2005 Jun; 48(7):1002-11. PubMed ID: 15857627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.
    Sevalle J; Ayral E; Hernandez JF; Martinez J; Checler F
    J Neurochem; 2009 Jul; 110(1):275-83. PubMed ID: 19457123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominance of amyloid precursor protein sequence over host cell secretases in determining beta-amyloid profiles studies of interspecies variation and drug action by internally standardized immunoprecipitation/mass spectrometry.
    Du P; Wood KM; Rosner MH; Cunningham D; Tate B; Geoghegan KF
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1144-52. PubMed ID: 17202404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [3H]-L-685,458 as a radiotracer that maps gamma-secretase complex in the rat brain: relevance to Abeta genesis and presence of active presenilin-1 components.
    Xiong K; Clough RW; Luo XG; Struble RG; Li YM; Yan XX
    Brain Res; 2007 Jul; 1157():81-91. PubMed ID: 17512915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of highly potent benzodiazepine gamma-secretase inhibitors: preparation of (2S,3R)-3-(3,4-difluorophenyl)-2-(4-fluorophenyl)-4- hydroxy-N-((3S)-1-methyl-2-oxo-5- phenyl-2,3-dihydro-1H-benzo[e][1,4]-diazepin-3-yl)butyramide by use of an asymmetric Ireland-Claisen rearrangement.
    Churcher I; Williams S; Kerrad S; Harrison T; Castro JL; Shearman MS; Lewis HD; Clarke EE; Wrigley JD; Beher D; Tang YS; Liu W
    J Med Chem; 2003 Jun; 46(12):2275-8. PubMed ID: 12773031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-substituted cyclohexyl sulfones as potent, orally active gamma-secretase inhibitors.
    Churcher I; Beher D; Best JD; Castro JL; Clarke EE; Gentry A; Harrison T; Hitzel L; Kay E; Kerrad S; Lewis HD; Morentin-Gutierrez P; Mortishire-Smith R; Oakley PJ; Reilly M; Shaw DE; Shearman MS; Teall MR; Williams S; Wrigley JD
    Bioorg Med Chem Lett; 2006 Jan; 16(2):280-4. PubMed ID: 16275079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors.
    Chang WP; Koelsch G; Wong S; Downs D; Da H; Weerasena V; Gordon B; Devasamudram T; Bilcer G; Ghosh AK; Tang J
    J Neurochem; 2004 Jun; 89(6):1409-16. PubMed ID: 15189343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.